Evidence map›Paper›PMID 33046752›Full record

ArticleScientific reports2020

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.

Kazutomo Niwa, Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Takashi Saotome, Masashi Okazaki, Keisuke Yamazaki, Isaku Okamoto, Hideaki Hirai, Natsuki Saigusa and 12 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Prognostic Significance of Neutrophil-Lymphocyte Ratio in Salivary Gland Neoplasms: A Systematic Review.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
    Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kazutomo Niwa *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan.
Daisuke Kawakita *Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8602, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, 160-0023, Japan.
Hideaki TakahashiDepartment of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Kanagawa, 236-0004, Japan.
Takashi SaotomeDivision of Medical Oncology, Matsudo City Hospital, Chiba, 270-2252, Japan.
Masashi OkazakiDepartment of Otorhinolaryngology, Head and Neck Surgery, Nihonkai General Hospital, Yamagata, 998-8501, Japan.
Keisuke YamazakiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8520, Japan.
Isaku OkamotoDepartment of Otorhinolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, 160-0023, Japan.
Hideaki HiraiDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, 160-0023, Japan.
Natsuki SaigusaDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, 160-0023, Japan.
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan.
Tatsuo MasubuchiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan.
Kouki MiuraDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan.
Shin-Ichi OkazakiDepartment of Otorhinolaryngology, Head and Neck Surgery, Nihonkai General Hospital, Yamagata, 998-8501, Japan.
Hirooki MatsuiDepartment of Otorhinolaryngology, Head and Neck Surgery, Nihonkai General Hospital, Yamagata, 998-8501, Japan.
Takuro OkadaDepartment of Otorhinolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, 160-0023, Japan.
Sho IwakiDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8602, Japan.
Takashi MatsukiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, 252-0375, Japan.
Kenji HanyuDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, 160-0023, Japan.
Nobuhiko OridateDepartment of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Kanagawa, 236-0004, Japan.
Yuichiro Tada *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, 108-8329, Japan. ytada@iuhw.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although immune-checkpoint inhibitors (ICIs) are effective against various cancers, little is known regarding their role in salivary gland carcinoma (SGC) treatment. Therefore, we evaluated the efficacy and safety of nivolumab monotherapy in patients with recurrent and/or metastatic SGC. In this multicentre retrospective study, nivolumab (240 mg) was administered every 2 weeks. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety were examined; the correlation between treatment outcomes and clinicopathological factors was analysed. Twenty-four patients were enrolled; the most common histopathology was salivary duct carcinoma. Eleven tumours were PD-L1-positive; no tumour was microsatellite instability-high. The ORR was 4.2%, and the median PFS and OS were 1.6 and 10.7 months, respectively. One patient continued nivolumab for 28 months without disease progression. One patient showed grade 4 increase in creatine phosphokinase levels and grade 3 myositis. Biomarker analysis revealed significantly increased OS in patients with performance status of 0; modified Glasgow prognostic score of 0; low neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and C-reactive protein; and high lymphocyte-to-monocyte ratio and in patients who received systemic therapy following nivolumab. Although nivolumab's efficacy against SGC was limited, some patients achieved long-term disease control. Further studies are warranted on ICI use for SGC.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, DuctalFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm MetastasisNivolumabRetrospective StudiesSalivary Gland NeoplasmsAntineoplastic Agents, ImmunologicalB7-H1 AntigenImmune Checkpoint InhibitorsNivolumab

Identifiers

PMID33046752
PMCPMC7552420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.